[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperthyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperthyroidism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,69,99,123,145,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100428242","phase-3-preoperative-lugols-solution-in-graves-disease-and-toxic-nodular-goiter-100428242",false,"NCT04856488","Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter","Inclusion Criteria:\n\n* Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 \\\u003C30 pmol\u002FL or Graves' disease\n* Signed informed consent\n\nExclusion Criteria:\n\n* Unstable coronary artery disease\n* Previous thyroid surgery\n* Congestive heart failure\n* Renal insufficiency\n* Hepatic failure\n* Current infection\n* Treatment with steroids or anticoagulants\n* Thyroid associated orbitopathy CAS \\> 2\n* Diabetes mellitus type 1\n* Active cancer\n* Severe psychiatric illness\n* Amiodarone treatment\n* Pregnancy\n* Breast feeding\n* Women of child bearing potential not using contraceptive\n* Inability to comprehend the meaning of the study\n* Iodine hypersensitivity","ALL","18 Years","75 Years",{"count":19,"type":20},182,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy",[26],"Hyperthyroidism","RECRUITING","2026-02-06",{"date":30,"type":31},"2026-02-10","ACTUAL",{"date":33,"type":31},"2021-11-18",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"Jan Calissendorff","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100624106","a-brief-video-intervention-to-improve-patient-outcomes-following-radioiodine-treatment-100624106","NCT07405320","A Brief Video Intervention to Improve Patient Outcomes Following Radioiodine Treatment","Testing a Brief Video Intervention to Support Patient Coping Following Radioiodine Treatment","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis of hyperthyroidism or thyroid cancer\n* Scheduled to receive radioiodine therapy at Auckland City Hospital Radiation Oncology Clinic\n* Able to understand and communicate in English\n* Access to an internet-connected device to complete study questionnaires\n\nExclusion Criteria:\n\n* Completed previous radioiodine treatment\n* Self-reported difficulty completing questionnaires",{"count":48,"type":20},80,[50],"NA","This study will test the impact of a short video intervention for people who are receiving radioiodine treatment for thyroid conditions (such as hyperthyroidism or thyroid cancer). After their single-dose treatment, patients need to follow safety instructions to protect others and manage side effects during recovery. Some people find these instructions hard to remember, and side effects (or anticipation of side effects) can feel worrying or disruptive. The video aims to present the treatment information in a more accessible patient-friendly way, so that patients feel less distressed, find their side effects easier to cope with, and better engage with safety precautions. All patients will first have a pre-treatment consultation with their doctor and receive the standard treatment information currently provided. Before this consultation patients will be randomly assigned to view one of two videos. The control group will see a neutral video that details standard health information that is not specific to radioiodine, while the intervention group will see a video that explains side effects, safety requirements and recovery period in a more adaptive way. Comparing these two groups will allow us to assess whether this new approach improves coping, reduces distress, and enhances adherence to safety instructions in the post-dose recovery phase of radioiodine treatment.",[53,26,54],"Thyroid Cancer","Radioiodine Treatment",[56,57,58],"Mindset","Digital Intervention","Radioiodine","NOT_YET_RECRUITING","2026-02-04",{"date":62,"type":31},"2026-02-12",{"date":64,"type":20},"2026-01-12",{"date":66,"type":20},"2026-07-06",{"name":68,"class":38},"University of Auckland, New Zealand",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":39},"100621318","phase-2-impact-of-vitamin-d-therapy-on-thyroid-function-and-antibody-levels-in-pediatric-graves-disease-100621318","NCT07369063","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility Trial","Inclusion Criteria:\n\n* All new pediatric participants aged 9-17 years with a new diagnosis of GD who will be started on methimazole, will be offered to participate at the time of diagnosis.\n* Biochemical features include:\n* Suppressed TSH \\\u003C0.1.\n* Elevated T3\n* Elevated Free T4\n* Elevated T4\n* Positive TSI or TRAb. The presence of antibodies is diagnostic.\n* Our study will offer enrollment to non-English speaking participants\n\nExclusion Criteria:\n\n* Initial hydroxy vitamin D levels \\>80 ng\u002FmL\n* Hypocalcemia, corrected calcium based on albumin \\\u003C8.4 mg\u002FdL\n* Hypercalcemia, corrected calcium based on albumin \\>10.5 mg\u002FdL\n* Conditions that affect vitamin D metabolism such as: malabsorption, chronic kidney or liver disease, nephrocalcinosis, hyperparathyroidism\n* Current use of medications which are known to affect thyroid function or vitamin D metabolism such as thyroid hormone replacement, corticosteroids, anticonvulsants\n* Allergy to vitamin D or methimazole\n* Diagnosis of Hashitoxicosis or thyrotoxicosis (both TSH receptor antibody (TRAb) and thyroid-stimulating immunoglobulin (TSI) levels are negative)\n* Participants under the age of 9 years at the time of diagnosis\n* Pregnant participants\n* Active or uncontrolled infections, other significant medical conditions deemed by the investigator to interfere with study participation or pose undue risk to the participant.","9 Years","17 Years",{"count":79,"type":20},30,[81],"PHASE2","The goal of this randomized pilot feasibility clinical trial is to determine the feasibility of implementing a protocol for a larger trial to assess the effects of high-dose vitamin D supplementation in pediatric patients (9-17 years old) newly diagnosed with Graves' disease. The main questions it aims to answer are:\n\nWhat are the recruitment and adherence rates for a larger trial using this protocol? Is the data collection process complete and robust enough for a larger trial? What are the potential barriers to implementing a larger-scale trial? Researchers will compare vitamin D supplementation plus standard methimazole therapy to methimazole therapy alone (with participants permitted to take up to 1000 International Units of vitamin D2 daily) to explore potential effects on thyroid hormone and antibody levels.\n\nParticipants will:\n\nBe randomized to either the intervention or control group. Take study medications (vitamin D or placebo) as directed. Attend regular study visits for blood tests and clinical assessments. Complete medication logs.",[84,85,26],"Graves Disease","Graves' Disease",[87,88,89],"vitamin d","graves disease","hyperthyroidism","2026-01-23",{"date":92,"type":31},"2026-01-27",{"date":94,"type":31},"2025-08-01",{"date":96,"type":20},"2027-02-28",{"name":98,"class":38},"Northwell Health",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":39},"100577123","hyperthyroidism-as-a-potential-predictive-of-worse-outcome-of-renal-graft-100577123","NCT06794203","Hyperthyroidism as a Potential Predictive of Worse Outcome of Renal Graft","Hyperthyroidism in the Immediate Post-kidney Transplantation Period: a Potential Predictive of Worse Outcome of Renal Graft","Inclusion Criteria:\n\n* Subjects transplanted at our Center;\n* Subjects whose 3-month follow-up is available;\n* Age ≥18 years;\n* Availability of clinical and laboratory data regarding thyroid function trends in the immediate post-transplant period (within 30 days after transplantation);\n* Subjects giving informed consent to participate.\n\nExclusion Criteria:\n\n* None.",{"count":107,"type":20},100,"OBSERVATIONAL","The objectives of the study are: to research the association, if any, between the occurrence of thyroid function changes in the immediate post-transplant period and the prognosis of the transplant itself; identify any risk factors for the occurrence of thyroid disorders In the immediate post-transplant period.",[111,112,26],"Kidney Diseases","Kidney Transplant",[26,111],"2025-01-24",{"date":116,"type":31},"2025-01-27",{"date":118,"type":31},"2022-09-02",{"date":120,"type":20},"2025-07-01",{"name":122,"class":38},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":15,"minAge":16,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100561568","evaluation-of-renal-function-in-patients-with-hyperthyroidism-100561568","NCT06591858","Evaluation of Renal Function in Patients With Hyperthyroidism","Evaluation of Renal Function in Patients With Subclinical and Overt Hyperthyroidism","Inclusion Criteria:\n\n* Patients aged (18\\_80 years) diagnosed subclinical and overt Hyperthyroidism with overt Hyperthyroidism\n\nExclusion Criteria:\n\n1. Patients with D.M\n2. Patients with Hypertension\n3. Patients with CKD or ESRD\n4. IHD\n5. Pateints receiving medication known to affect renal function as contrast agent, non-steroidal anti-inflammatory drugs and ACEIs",true,"80 Years",{"count":133,"type":20},50,"To evaluate the effect of subclinical and overt Hyperthyroidism in renal function",[26],"2024-09-09",{"date":138,"type":31},"2024-09-19",{"date":140,"type":20},"2024-09",{"date":142,"type":20},"2026-05",{"name":144,"class":38},"Assiut University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":156,"studyType":108,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":39},"100559963","a-clinical-study-of-hyperthyroidism-in-children-100559963","NCT06570967","A Clinical Study of Hyperthyroidism in Children","A Retrospective and Prospective Observational Study of Hyperthyroidism in Children","Inclusion Criteria:\n\n1. Age ≤14 years old\n2. Initial diagnosis of hyperthyroidism\n\nExclusion Criteria:\n\n1. Hyperthyroidism had been treated with medication in other hospitals,\n2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation,\n3. Patients with incomplete clinical data","29 Days","14 Years",{"count":155,"type":20},1000,"10 Years","This study intends to conduct a retrospective and prospective study on children with hyperthyroidism, and it is a non-intervention study to collect information on diagnosis and treatment and long-term follow-up of children with hyperthyroidism. To investigate the clinical characteristics, treatment effect, side effects and remission of hyperthyroidism in children, to analyze the predictive factors for the effect of antithyroid drug treatment, remission and recurrence after drug withdrawal, and to explore the risk factors related to the occurrence of antithyroid drug-related adverse reactions.",[26],"2024-08-24",{"date":161,"type":31},"2024-08-27",{"date":163,"type":31},"2023-07-18",{"date":165,"type":20},"2027-12",{"name":167,"class":38},"Shengjing Hospital",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100557619","iodine-supplementation-in-graves-hyperthyroidism-100557619","NCT06540469","Iodine Supplementation in Graves' Hyperthyroidism","Effects of Optimal Iodine Supplementation in Anti-thyroid Drug Therapy for Graves' Hyperthyroidism: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. patients newly diagnosed with Graves' hyperthyroidism and not treated; or\n2. patients diagnosed with Graves' hyperthyroidism and treated with ATDs regularly less than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb is positive; or\n3. patients diagnosed with Graves' hyperthyroidism and not regularly treated with ATDs more than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb is positive.\n\nExclusion Criteria:\n\n1. thyroid enlargement of grade 3;\n2. serum TRAb is measured above 40IU\u002FL;\n3. moderate or severe thyroid-associated eye diseases;\n4. hepatic disease history including chronic active hepatitis, severe hepatic dysfunction, liver cirrhosis, etc., and serum transaminase level is 3 times higher than the upper normal limit and\u002For total bilirubin level is higher than 34.2μmol\u002FL with hepatic protective drugs;\n5. history of moderate-to-severe or end-stage renal disease: eGFR\\\u003C60mL\u002Fmin\u002F1.73m2 with simplified MDRD formula;\n6. serum WBC\\\u003C3.0×109／L or neutrophil count\\\u003C1.5×109／L;\n7. history of severe cardiocerebrovascular disease, digestive disease, hematopoietic system disease, other autoimmune diseases in addition to Graves' hyperthyroidism, tumors, psychosis, etc.;\n8. blood pressure\\>180\u002F100mmHg with regular antihypertensive drugs treatment;\n9. severe comorbidities and complications of hyperthyroidism with ATDs treatment;\n10. history of multiple drug allergies;\n11. a family planning plan in 3 years.","70 Years",{"count":177,"type":20},315,[50],"In China, the morbidity of thyroid diseases is high and the harm is serious. Iodine is closely related to thyroid diseases. It should be paid attention to guide patients to supplement iodine scientifically. Thyroid iodine uptake in hyperthyroidism patients is enhanced, and patients are generally advised to limit iodine intake in clinical practice. However, recent studies suggest that there is no definite conclusion on whether patients with hyperthyroidism should strictly limit iodine intake. The purpose of this study is to establish a national multi-center iodine intervention cohort for patients with Graves' hyperthyroidism, identify the effects of different iodine intake on hyperthyroidism, and establish iodine intervention program for hyperthyroidism. This study is a multicenter, prospective, open-level, randomized, controlled, parallel group clinical trial with a total sample size of 315 cases, a total of 3 participating units, each of which completed 105 cases. All subjects meeting the inclusion criteria were completely randomized in each center according to the random procedure with a probability of 1:1:1: ① Iodine Supplementation in Whole Course of Treatment with ATDs; ② Iodine Supplementation During Maintenance Treatment with ATDs; ③ Iodine Restriction in Whole Course of Treatment with ATDs. Information was collected before ATD treatment, at 3 months, 6 months, 12 months, 18 months (withdrawal), 6 months and 12 months after ATDs withdrawal. The primary purpose of this study is to analyze the difference in remission rate of hyperthyroidism between different iodine nutritional interventions. At the same time, the differences of duration from initiation to withdrawal of ATDs, duration from initiation of ATDs to thyroid function (including serum FT3, FT4 and TSH) normalization, duration from initiation of ATDs to serum FT3 and FT4 normalization, quality of life (QOL) in patients with Graves' hyperthyroidism, adverse effects rate of ATDs treatment, duration from initiation of ATDs to serum negative TRAb is first measured were observed.",[84,26],[85,26,182,183],"Iodine Supplementation","Anti-Thyroid Drug","2024-08-03",{"date":186,"type":31},"2024-08-06",{"date":188,"type":20},"2024-08-01",{"date":190,"type":20},"2028-07-31",{"name":192,"class":193},"Shandong Provincial Hospital","OTHER_GOV"]